India to waive import duty on coronavirus vaccines, says government source

The Indian government currently regulates the sale and purchase of all coronavirus shots in the country

vaccines, Sanofi Pasteur
Reuters NEW DELHI
2 min read Last Updated : Apr 20 2021 | 7:33 AM IST

By Aftab Ahmed

NEW DELHI (Reuters) - India will waive its 10% customs duty on imported COVID-19 vaccines, a senior government official told Reuters on Monday, as it tries to boost supplies to counter a dramatic surge in coronavirus cases.

Imports of Russia's Sputnik V vaccine are due to arrive soon and the government has also urged Pfizer, Moderna and Johnson and Johnson to sell their products to India.

The official, who declined to be named, also said the government was considering allowing private entities to import approved vaccines for sale on the open market without government intervention. They could also be given the freedom to set pricing, he added.

The Indian government currently regulates the sale and purchase of all COVID-19 shots in the country.

A finance ministry spokesman did not immediately respond to an email seeking comment outside business hours.

Other South Asian countries, including Nepal and Pakistan, as well as Latin American nations such as Argentina and Brazil levy vaccine import tariffs ranging between 10% and 20%.

New COVID-19 infections and deaths in India have jumped by record numbers for days, with hospitals running short of beds, oxygen and key medicines. Total deaths have swelled to nearly 179,000 and cases have climbed above 15 million, the world's second highest tally behind the United States.

The government has now decided to open vaccinations for all adults from May 1.

 

(Reporting by Aftab Ahmed; Additional reporting by Krishna N. Das; Editing by David Goodman)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Apr 20 2021 | 7:29 AM IST

Next Story